Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-142-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0013H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood

Sample Requirements

10 µl/well

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 2.6%

Inter-assay (Run-to-Run)

n = 5,
CV = 13.3%

Spiking Recovery

101.2%

Dilutation Linearity

98.4%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-142-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Renal disease

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

The gene encoding hsa-miR-142-5p is located on the human chromosome 17. hsa-miR-142-5p is highly specific for hematopoietic cells and is overexpressed in pathological conditions such as cancer, immunologically related disorders, small bowel inflammation, renal fibrosis where inflammation occurs and in biopsies from renal transplant patients with acute rejection. It has been suggested that overexpression of hsa-miR-142-5p in patients with chronic antibody-mediated rejection is associated with immunological disorders rather than renal dysfunction. Furthermore, hsa-miR-142-5p may play an onco-miRNA role in progression of renal cell carcinoma.

hsa-miR-142-5p was shown to be downregulated in hepatocellular carcinoma cells and to suppress hepatocelullar carcinoma cell migration. Moreover hsa-miR-142-5p is related to recurrence risk in gastric cancer patients. miRNAs are also implicated in normal heart development and function as well as in cardiac disorders. Downregulation of hsa-miR-142-5p was described in cardiac hypertrophy. Moreover, altered levels of hsa-miR-142-5p in blood were described in dilated cardiomyopathy.

References to Summary

References to miR-142-5p

  • TSANG, Felice Ho-Ching, et al. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. Frontiers of medicine, 2015, 9.3: 331-343.
  • ZHANG, X., et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Annals of oncology, 2011, 22.10: 2257-2266.
  • LANDGRAF, Pablo, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 2007, 129.7: 1401-1414.
  • DANGER, Richard, et al. Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection. PloS one, 2013, 8.4: e60702.
  • ANGLICHEAU, Dany, et al. MicroRNA expression profiles predictive of human renal allograft status. Proceedings of the National Academy of Sciences, 2009, 106.13: 5330-5335.
  • LIU, Lingqi, et al. MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3. American journal of translational research, 2017, 9.5: 2394.
  • SHARMA, Salil, et al. Repression of miR‐142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. EMBO molecular medicine, 2012, 4.7: 617-632.
  • BARSANTI, Cristina, et al. Differential regulation of microRNAs in end-stage failing hearts is associated with left ventricular assist device unloading. BioMed research international, 2015, 2015.
  • VOELLENKLE, Christine, et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiological genomics, 2010, 42.3: 420-426.
Related Products Documents